3 unchanged sentences
Holders of Our Common Stock
−Removed: As of March 3, 2022, there were approximately 83 registered holders of record of our common stock.
−Removed: The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in “street name” by brokers or held by other “nominees”.
+Added: As of February 27, 2023, there were approximately 60 registered holders of record of our common stock.
+Added: The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are
+Added: beneficial owners, but whose shares are held in “street name” by brokers or held by other “nominees”.
The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
5 unchanged sentences
Unregistered Sales of Equity Securities
−Removed: In December 2021, we acquired BioArkive, Inc.
−Removed: (“BioArkive”) and in exchange issued to BioArkive and its shareholders 379,635 shares of Immuneering’s Class A common stock, which was calculated using a value of $8.75 million divided by the average of the daily volume weighted average prices of the Class A common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing.
−Removed: These shares were offered and sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
+Added: During the period covered by this Annual Report on Form 10-K, we did not issue any securities which were unregistered under the Securities Act and required to be disclosed herein.
Issuer Purchases of Equity Securities
We did not purchase any of our registered equity securities during the quarterly period ended December 31, 2022.
−Removed: Securities Authorized for Issuance Under Equity Compensation Plans
−Removed: Information about our equity compensation plans will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.